Review



anti p2y12 receptor extracellular pe antibody  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Alomone Labs anti p2y12 receptor extracellular pe antibody
    Anti P2y12 Receptor Extracellular Pe Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Anti-P2Y12+Receptor+(extracellular)-PE+Antibody/pm41980755-59-32-37
    Average 94 stars, based on 3 article reviews
    anti p2y12 receptor extracellular pe antibody - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation.
    Article Snippet: Cells were reconstituted in fully supplemented culture medium and incubated in the presence or absence of anti-CD3/CD28 antibody-coated microbeads for up to 30 min at 37 °C and 5% CO2. .. Cells were fixed with 4% paraformaldehyde in PBS for 10 min, incubated with blocking buffer (1% BSA and 0.3 M glycine in PBS) for 1 h, and stained with antibodies (1:100) directed against extracellular epitopes of human P2Y1 or P2Y12 receptors (Alomone Labs) overnight. .. Cells were washed and incubated with DyLight488-labeled secondary antibodies (1:2000; Biolegend) for 1 h, and receptor expression was assessed with a Leica DMI6000B inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany) using a fluorescein isothiocyanate (FITC) filter set, a ×100 oil objective (numerical aperture [NA] 1.3), and a Leica DFC365 FX camera.

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation
    Article Snippet: Cells were reconstituted in fully supplemented culture medium and incubated in the presence or absence of anti-CD3/CD28 antibody-coated microbeads for up to 30 min at 37 °C and 5% CO 2 . .. Cells were fixed with 4% paraformaldehyde in PBS for 10 min, incubated with blocking buffer (1% BSA and 0.3 M glycine in PBS) for 1 h, and stained with antibodies (1:100) directed against extracellular epitopes of human P2Y1 or P2Y12 receptors (Alomone Labs) overnight. .. Cells were washed and incubated with DyLight488-labeled secondary antibodies (1:2000; Biolegend) for 1 h, and receptor expression was assessed with a Leica DMI6000B inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany) using a fluorescein isothiocyanate (FITC) filter set, a ×100 oil objective (numerical aperture [NA] 1.3), and a Leica DFC365 FX camera.

    Blocking Assay:

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation.
    Article Snippet: Cells were reconstituted in fully supplemented culture medium and incubated in the presence or absence of anti-CD3/CD28 antibody-coated microbeads for up to 30 min at 37 °C and 5% CO2. .. Cells were fixed with 4% paraformaldehyde in PBS for 10 min, incubated with blocking buffer (1% BSA and 0.3 M glycine in PBS) for 1 h, and stained with antibodies (1:100) directed against extracellular epitopes of human P2Y1 or P2Y12 receptors (Alomone Labs) overnight. .. Cells were washed and incubated with DyLight488-labeled secondary antibodies (1:2000; Biolegend) for 1 h, and receptor expression was assessed with a Leica DMI6000B inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany) using a fluorescein isothiocyanate (FITC) filter set, a ×100 oil objective (numerical aperture [NA] 1.3), and a Leica DFC365 FX camera.

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation
    Article Snippet: Cells were reconstituted in fully supplemented culture medium and incubated in the presence or absence of anti-CD3/CD28 antibody-coated microbeads for up to 30 min at 37 °C and 5% CO 2 . .. Cells were fixed with 4% paraformaldehyde in PBS for 10 min, incubated with blocking buffer (1% BSA and 0.3 M glycine in PBS) for 1 h, and stained with antibodies (1:100) directed against extracellular epitopes of human P2Y1 or P2Y12 receptors (Alomone Labs) overnight. .. Cells were washed and incubated with DyLight488-labeled secondary antibodies (1:2000; Biolegend) for 1 h, and receptor expression was assessed with a Leica DMI6000B inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany) using a fluorescein isothiocyanate (FITC) filter set, a ×100 oil objective (numerical aperture [NA] 1.3), and a Leica DFC365 FX camera.

    Staining:

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation.
    Article Snippet: Cells were reconstituted in fully supplemented culture medium and incubated in the presence or absence of anti-CD3/CD28 antibody-coated microbeads for up to 30 min at 37 °C and 5% CO2. .. Cells were fixed with 4% paraformaldehyde in PBS for 10 min, incubated with blocking buffer (1% BSA and 0.3 M glycine in PBS) for 1 h, and stained with antibodies (1:100) directed against extracellular epitopes of human P2Y1 or P2Y12 receptors (Alomone Labs) overnight. .. Cells were washed and incubated with DyLight488-labeled secondary antibodies (1:2000; Biolegend) for 1 h, and receptor expression was assessed with a Leica DMI6000B inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany) using a fluorescein isothiocyanate (FITC) filter set, a ×100 oil objective (numerical aperture [NA] 1.3), and a Leica DFC365 FX camera.

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation
    Article Snippet: Cells were reconstituted in fully supplemented culture medium and incubated in the presence or absence of anti-CD3/CD28 antibody-coated microbeads for up to 30 min at 37 °C and 5% CO 2 . .. Cells were fixed with 4% paraformaldehyde in PBS for 10 min, incubated with blocking buffer (1% BSA and 0.3 M glycine in PBS) for 1 h, and stained with antibodies (1:100) directed against extracellular epitopes of human P2Y1 or P2Y12 receptors (Alomone Labs) overnight. .. Cells were washed and incubated with DyLight488-labeled secondary antibodies (1:2000; Biolegend) for 1 h, and receptor expression was assessed with a Leica DMI6000B inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany) using a fluorescein isothiocyanate (FITC) filter set, a ×100 oil objective (numerical aperture [NA] 1.3), and a Leica DFC365 FX camera.

    other:

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation
    Article Snippet: Rabbit P2Y1 (Cat. # APR-021) and P2Y12 (Cat. # APR-020) antibodies recognizing extracellular epitopes of human P2Y1 and P2Y12 receptors, respectively, were purchased from Alomone Labs (Jerusalem, Israel).

    Article Title: Autocrine stimulation of P2Y1 receptors is part of the purinergic signaling mechanism that regulates T cell activation.
    Article Snippet: Rabbit P2Y1 (Cat. # APR-021) and P2Y12 (Cat. # APR-020) antibodies recognizing extracellular epitopes of human P2Y1 and P2Y12 receptors, respectively, were purchased from Alomone Labs (Jerusalem, Israel).



    Similar Products

    94
    Alomone Labs anti p2y12 receptor extracellular pe antibody
    Anti P2y12 Receptor Extracellular Pe Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Anti-P2Y12+Receptor+(extracellular)-PE+Antibody/pm41980755-59-32-37
    Average 94 stars, based on 1 article reviews
    anti p2y12 receptor extracellular pe antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress p2y12 receptor antagonist cangrelor
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    P2y12 Receptor Antagonist Cangrelor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/P2RY12+Antibody/pmc13032217-121-25-29
    Average 94 stars, based on 1 article reviews
    p2y12 receptor antagonist cangrelor - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    99
    Oxford Instruments imaris
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    Imaris, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Imaris/custom%40imaris%4010%2E64898%2F2026%2E07%2E22%2E740167
    Average 99 stars, based on 1 article reviews
    imaris - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    94
    Alomone Labs anti p2y12 receptor antibody
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    Anti P2y12 Receptor Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Anti-P2Y12+Receptor+Antibody/pm41980755-59-70-73
    Average 94 stars, based on 1 article reviews
    anti p2y12 receptor antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Alomone Labs anti p2y12r antibody
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    Anti P2y12r Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Anti-P2Y12+Receptor+Antibody/pm41787372-50-24-26
    Average 94 stars, based on 1 article reviews
    anti p2y12r antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Alomone Labs anti p2y 12 antibody
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    Anti P2y 12 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Anti-P2Y12+Receptor+Antibody/pmc13072548-19-17-25
    Average 94 stars, based on 1 article reviews
    anti p2y 12 antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Alomone Labs anti p2y12 antibody
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    Anti P2y12 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Anti-P2Y12+Receptor+Antibody/pm41787372-24-14-21
    Average 94 stars, based on 1 article reviews
    anti p2y12 antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Alomone Labs anti p2y 12 r antibody
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    Anti P2y 12 R Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/Anti-P2Y12+Receptor+Antibody/pmc13072548-43-26-30
    Average 94 stars, based on 1 article reviews
    anti p2y 12 r antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    86
    Galectin Therapeutics p2y12 receptors
    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted <t>Bannakunin-P2Y12</t> receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls
    P2y12 Receptors, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p2y12+receptors/p2y12+receptors/10__1172_slash_jci199706-146-15-20
    Average 86 stars, based on 1 article reviews
    p2y12 receptors - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted Bannakunin-P2Y12 receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls

    Journal: Cellular & Molecular Biology Letters

    Article Title: Bannakunin: a dual-target Kunitz inhibitor bridging anticoagulation (FXa/XIIa) and anti-platelet (α2β1/P2Y12) pathways

    doi: 10.1186/s11658-026-00862-7

    Figure Lengend Snippet: Mechanistic regulation of ADP-mediated platelet activation by Bannakunin. A Aggregometric responses to ADP (2 μM) in PRP pretreated with: Bannakunin (1 μM), cangrelor (1 μg/ml) or combinatorial therapy (Bannakunin + cangrelor). B Comparative inhibition profiles of ADP-induced aggregation (2 μM) under pre-treatment conditions: Bannakunin (1 μM), MRS2179 (1 μg/ml) or dual-agent administration (Bannakunin + MRS2179). C Molecular docking simulations predicted Bannakunin-P2Y12 receptor interactions, with intermolecular hydrogen-bond networks (yellow dashes) stabilising the complex (Bannakunin: purple; P2Y12: green). D Cyclic AMP (cAMP) levels were quantified in ADP-activated platelets (2 μM) following Bannakunin pretreatment. E Immunoblot analysis of PI3K/AKT phosphorylation cascades in ADP-stimulated platelets (2 μM) exposed to escalating Bannakunin concentrations (0.25–1 μM). Representative blots and densitometric quantitation demonstrate dose-dependent kinase modulation. Triplicate experiments are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001; ns, non-significant variation versus untreated controls

    Article Snippet: Furthermore, platelet-rich plasma (PRP) was pre-treated with or without the following inhibitors before collagen stimulation: a P2Y1 receptor antagonist MRS2179 (MCE, USA, 2 μg/mL), a P2Y12 receptor antagonist cangrelor (MCE, USA, 2 μg/ml) and aspirin (a cyclooxygenase inhibitor, MCE, USA,2 μg/mL).

    Techniques: Activation Assay, Inhibition, Western Blot, Phospho-proteomics, Quantitation Assay